Tarsa Completes Phase III For Oral Calcitonin In Osteoporosis, Plans 2011 NDA
This article was originally published in The Pink Sheet Daily
Executive SummaryInitially, biotech will pursue a treatment indication but also has its recombinant oral formulation in Phase II for osteoporosis prevention.
You may also be interested in...
Plus news on recent financing activity by Aastrom Biosciences, Tarsa Therapeutics, OncoGenex and Medivation.
Privately held firm believes oral calcitonin will enjoy several advantages over other osteoporosis therapies – ease of use compared to calcitonin nasal spray and safety compared to bisphosphonates.